Targeted Genetics Corporation develops innovative molecular therapeutics for the prevention and treatment of acquired and inherited diseases with significant unmet medical need. The company’s proprietary Adeno-Associated Virus (AAV) technology platform allows for the delivery of protein-encoded genes to increase gene function and the delivery of RNAi to decrease or silence gene function. Targeted Genetics’ product development efforts target inflammatory arthritis, AIDS prophylaxis, congestive heart failure, Huntington’s Disease and Leber Congenital Amaurosis.
|
